Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P170. Paediatric inflammatory bowel disease in Greece: 30 years experience of a single center
P170. Prevalence of hepatitis B viral markers in Korean patients with inflammatory bowel disease: ineffective antibody formation in young patients
Authors:

E.Y. Kim1, K.B. Cho2, E.S. Kim2, K.S. Park2, S.W. Jeon3, W.J. Kim4, K.O. Kim5, B.I. Jang5, C.H. Yang6, 1Catholic University of Daegu School of Medicine, Internal Medicine, Daegu, South Korea, 2Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea, 3Kyungpook National University School of Medicine, Internal Medicine, Daegu, South Korea, 4Soon Chun Hyang University, Internal Medicine, Kumi, South Korea, 5Yeungnam University College of Medicine, Internal Medicine, Daegu, South Korea, 6Dongguk University Hospital, Internal Medicine, Kyungju, South Korea

P170

Comparison between elderly onset and adult onset inflammatory bowel disease

Authors:

C. Ricci*1, C. Pirali2, F. Lanzarotto1, G. Romanelli2, A. Lanzini1

1University of Brescia, Department of Molecular and Translational Medicine, Gastroenterology Unit, Spedali Civili, Brescia, Italy, 2University of Brescia, Department of Molecular and Translational Medicine, Geriatric Unit, Spedali Civili, Brescia, Italy

P171.

Physiological intermolecular modification spectroscopy (PIMS) for the prediction of response to anti-TNF therapy in patients with inflammatory bowel diseases

Authors:

P. Eftekhari1, L. Glaubitz2, M. Breidert3, R. Atreya4, 1INOVIEM Scientific, Bas Rhein, strasbourg, France, 2Medical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, 3Distric Hospital Kösching, Eichstätt, Teaching Hospital Technical University Munich, Kösching, Germany, 4CNRS UPR 3572, Laboratoire d'Immunopathologie et Chimie Thérapeutique, Strasbourg, France

P171. MMX® mesalazine 2.4 g/day for the maintenance of disease quiescence: Efficacy in patients with ulcerative colitis, regardless of prior treatment
P171. Prevalence of Crohn's disease in patients with spondyloarthropathies: interim analysis of the SPaCE study
Authors:

U. Kopylov1, B. Adelson1, M. Starr2, C. Watts2, E. Seidman1, 1McGill University Health Center, Center for IBD research, Montreal, Canada, 2McGill University Health Center, Rheumatology, Montreal, Canada

P171. Translation from guidelines to practice, use of endoscopy for initial diagnosis of IBD [on behalf of Dutch Delta IBD group]
P171

Smoking is associated with watery diarrhea and decreased likelihood to achieve clinical remission in collagenous colitis

Authors:

A. Münch*1, J. Bohr2, A. Madisch3, O. Bonderup4, C. Tysk5, M. Ström6, R. Mohrbacher7, R. Mueller7, R. Greinwald7, S. Miehlke8

1University hospital, Gastroenterology, Linköping, Sweden, 2University hospital, Gastroenterology, Örebro, Sweden, 3Siloah Hospital, Medical Department I, Hannover, Germany, 4Regional Hospital, Gastroenterology, Silkeborg, Sweden, 5University Hospital, Gastoenterology and Hepatology, Örebro, Sweden, 6Univeristy hospital, Gastroenterology, Linköping, Sweden, 7Dr. Falk Pharma, Research, Freiburg, Germany, 8Center for Digestive Diseases, Internal Medicine, Hamburg, Germany

P172.

Photodynamic surveillance of colitis-associated dysplasia in patients with ulcerative colitis and in mouse model, by visualization following oral 5-amino­levulinic acid sensitization

Authors:

T. Iwasaki1, T. Kato2, N. Komoike1, H. Saijo1, R. Sawada1, M. Saruta1, S. Arihiro1, M. Matsuoka1, S. Koido1, M. Ito3, S. Homma3, H. Tajiri1,2, 1The Jikei University School of Medicine, Gastroenterology and Hepatology, Tokyo, Japan, 2The Jikei University School of Medicine, Endoscopy, Tokyo, Japan, 3The Jikei University School of Medicine, Institute of DNA Medicine, Tokyo, Japan

P172. Fecal calprotectin (FC) is a useful early predictive marker for postoperative recurrence in Crohn's disease (CD)
P172. Mucosal TNF-alpha level as a criterion for when to stop treatment with adalimumab in patients with Crohn's disease? A preliminary report
P172. Prevalence and predictive factors of low bone mineral density in new onset of inflammatory bowel disease
Authors:

N. Ben Mustapha1, M. Cheikh2, H. Dabbabi2, M. Serghini2, L. Kallel2, J. Boubaker2, M. Fekih2, A. Filali2, 1La Rabta Hospital, Gastro A Unit, Tunis, Tunisia, 2La Rabta Hospital, Gastro A unit, Tunis, Tunisia

P172

Clinical and biological predictors of fatigue in Inflammatory Bowel Disease patients

Authors:

A. Villoria*1, V. García2, A. Dosal3, L. Moreno3, A. Montserrat1, A. Figuerola1, X. Calvet1

1Corporació Sanitària Universitària Parc Taulí, Digestive Disease Department. Departament de Medicina. Universitat Autònoma de Barcelona. CIBEREHD – Instituto de Salud Carlos III, Sabadell, Spain, 2Corporació Sanitària Universitària Parc Taulí, Digestive Disease Department., Sabadell, Spain, 3Corporació Sanitària Universitària Parc Taulí, Digestive Disease Department, Sabadell, Spain

P173.

Peroxisome proliferator-activated receptors family is involved in the response to treatment and clinical course in patients with ulcerative colitis

Authors:

J. Yamamoto-Furusho, M. Jacintez-Cazares, G. Fonseca-Camarillo, IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico

P173. An international survey on ulcerative colitis: Perspectives from patients and healthcare professionals
P173. Ehealth: Optimization of infliximab treatment and disease course via self-initiated web-based solution in Crohn's disease
P173. Predictors of long-term outcomes of perianal fistulizing Crohn's disease
Authors:

B. Tchoundjeu1, T. Rohou2, G. Bouguen1, D. Cuen1, T. Wallenhorst1, I. Berkelmans1, Y. Gandon2, J.-F. Bretagne1, L. Siproudhis1, 1CHU Pontchaillou, Service des Maladies de l'Appareil Digestif, Rennes, France, 2CHU Pontchaillou, Fédération d'Imagerie Médicale, Rennes, France

P173

Contrast-enhancement at magnetic resonance enterography does not differentiate between fibrosis and inflammation in Crohn's disease: a prospective cohort study

Authors:

G. Fiorino*1, A. Spinelli2, C. Bonifacio3, P. Spaggiari4, F. Grizzi5, A. Gandelli1, E. Morenghi6, M. Allocca1, M. Sacchi2, M. Roncalli4, L. Balzarini3, M. Montorsi2, A. Malesci7, 8, S. Vetrano1, S. Danese1

1Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy, 2Humanitas Research Hospital, IBD Surgery, Colo-rectal Surgery, Rozzano, Milan, Italy, 3Humanitas Research Hospital, Radiology, Rozzano, Milan, Italy, 4Humanitas Research Hospital, Anatomopathology, Rozzano, Milan, Italy, 5Humanitas Research Hospital, Immunology and Inflammation , Rozzano, Milan, Italy, 6Humanitas Research Hospital, Biostatistic, Rozzano, Milan, Italy, 7Humanitas Research Hospital, Gastroenterology, Rozzano, Milan, Italy, 8University of Milan, Translational Medicine, Milan, Italy

P174.

Pediatric ulcerative colitis; presenting features, therapeutic approach and disease course

Authors:

J. Martín de Carpi1, H. Expósito de Mena1,2, G. Pujol Muncunill2, V. Varea Calderón2, 1Hospital Sant Joan de Déu, Barcelona, Spain, Pediatric Inflammatory Bowel Disease Unit, Barcelona, Spain, 2Hospital Sant Joan de Deu, Pediatric Gastroenterology and Nutrition Unit, Barcelona, Spain

P174. Is there a difference between self-assessed patient-reported outcome and physician evaluation in ulcerative colitis? Results from a study with interferon-β-1a